Inj. romosozumab-aqqg 1 mg
Products billed under this code include Evenity.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Evenity.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Evenity | Amgen Inc | 55513-0880-02 | 210 | $2,686.32 |
| Evenity | Amgen Inc | 55513-0998-02 | 210 | $2,686.32 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $12.792 | +$0.06 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $12.732 | +$0.545 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $12.187 | +$0.078 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $12.109 | +$0.039 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $12.07 | +$0.066 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $12.004 | +$0.51 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $11.494 | +$0.008 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $11.486 | +$0.316 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $11.17 | +$0.015 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $11.155 | +$0.463 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted June 11, 2025 |
| 2Q24 | $10.692 | −$0.035 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted March 11, 2025 |
| 1Q24 | $10.727 | +$0.38 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted December 19, 2024 |
| 4Q23 | $10.347 | −$0.02 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted October 10, 2024 |
| 3Q23 | $10.367 | +$0.47 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted June 5, 2024 |
| 2Q23 | $9.897 | −$0.06 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted February 23, 2024 |
| 1Q23 | $9.957 | +$0.157 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted December 6, 2023 |
| 4Q22 | $9.80 | +$0.10 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted June 22, 2023 |
| 3Q22 | $9.70 | +$0.382 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted June 9, 2023 |
| 2Q22 | $9.318 | −$0.015 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted December 14, 2022 |
| 1Q22 | $9.333 | −$0.011 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted June 8, 2022 |
| 4Q21 | $9.344 | +$0.038 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted June 2, 2022 |
| 3Q21 | $9.306 | +$0.32 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted June 2, 2022 |
| 2Q21 | $8.986 | −$0.016 | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted March 1, 2022 |
| 1Q21 | $9.002 | – | 1 MG | Inj. romosozumab-aqqg 1 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.